Integrity Applications, GlucoTrack® Innovator, Names David Podwalski as Chief Commercial Officer

Fusion Marketplace Changes Healthcare Traveler Experience

Fusion Marketplace is a traveler-first driven platform giving healthcare professionals the power to make decisions in their careers that they haven't been able to in the past.

Veranex Announces Investment From Summit Partners to Form Comprehensive Concept-to-Commercialization Medtech Services Company

As the first phase in building this global entity, Veranex has acquired three complementary solution providers: Ximedica, Quartesian, and Boston Healthcare Associates. By bringing these companies together, Veranex combines the industry’s key pillars of design and engineering, regulatory, clinical, and market access into a single-source solution.

Integrity Applications, Inc. (OTCQB: IGAP), maker of GlucoTrack®, a non-invasive device for measuring glucose levels in people with type 2 diabetes and prediabetes, today announced the appointment of David Podwalski as Chief Commercial Officer.

The company reports that Mr. Podwalski is a seasoned pharmaceutical and life sciences executive with more than 20 years of experience in global commercial leadership, most notably with insulin-based therapies. Most recently, he served at Ernst & Young as Senior Consultant and Subject Matter Expert, Life Sciences, where he assisted major pharmaceutical, animal health, diagnostic, and medical device companies in developing innovative go-to-market commercial strategies, sales and marketing excellence programs, product launch roadmaps, commercial operations and analytics support, and enhanced patient and physician support services.

Previously, Mr. Podwalski was Senior Director of Global Commercial Effectiveness at Aventis Pharmaceuticals, where he designed and established leading practices in sales and marketing capabilities in the US, Europe, Asia and Latin America. While at Aventis, Mr. Podwalski provided global commercial leadership in the development of the global insulin business and improved pen delivery systems. Mr. Podwalski successfully launched Lantus and the Insulin Pen Delivery system in the United States, Germany, Japan and multiple other countries. This innovative basal insulin achieved peak sales of more than $9 billion, and has cumulative sales of more than $65 billion. Earlier in his career, Mr. Podwalski served in various capacities at Hoechst Marion Roussel Inc., including senior commercial leadership positions in both pharmaceutical and consumer healthcare products, most notably in diabetes.

John Graham, CEO and Chairman of Integrity Applications, remarked, “We are excited to have David join the Integrity Applications’ team. His extensive commercial and marketing background in diabetes, including driving sales and marketing for numerous new and relaunched products in the medical device industry, will be advantageous as we prepare to expand GlucoTrack commercial initiatives and implement strategies to capture a substantial portion of the market for non-invasive glucose monitoring in prediabetes and type 2 diabetes.”

“I am pleased to be joining Integrity Applications at such an exciting time in the company’s growth. We are seeing the convergence of glucose monitoring technology and digital health for diabetes, and I am enthusiastic about the commercial opportunities for GlucoTrack. There is an urgent need to transform diabetes management and to slow the progression of the diabetes epidemic. We believe that GlucoTrack, a non-invasive and patient-friendly approach to glucose monitoring, has significant potential in these large and clinically important markets,” replied Podwalski.



Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles